Long-Term Cardiovascular Safety of Lasmiditan for the Acute Treatment of Migraine for up to One Year: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)

被引：0
|
作者：
Rosen, N. L. [1 ]
Mathew, P. G. [2 ]
Buchanan, A. S. [3 ]
Baygani, S. [3 ]
Hochstetler, H. [4 ]
Khanna, R. [3 ]
机构：
[1] Donald & Barbara Zucker Sch Med Hofstra Northwell, Hempstead, NY USA
[2] Harvard Med Sch, Brigham & Womens Hosp, Sharon, MA USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Lilly USA LLC, Indianapolis, IN USA
来源：
HEADACHE | 2020年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：111 / 111
页数：1
相关论文
共 50 条
  • [1] LONG-TERM CARDIOVASCULAR SAFETY OF LASMIDITAN FOR THE ACUTE TREATMENT OF MIGRAINE FOR UP TO ONE YEAR: INTERIM RESULTS OF AN OPEN-LABEL PHASE 3 STUDY (GLADIATOR)
    Buchanan, Andrew
    Baygani, Simin K.
    Rosen, Noah
    Mathew, Paul G.
    Hochstetler, Helen
    Khanna, Rashna
    [J]. CEPHALALGIA, 2020, 40 : 49 - 50
  • [2] Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
    Brandes, Jan
    Kudrow, David
    Klise, Suzanne
    Krege, John H.
    Case, Michael
    Raskin, Joel
    Khanna, Rashna
    Vasudeva, Raghavendra
    [J]. NEUROLOGY, 2019, 92 (15)
  • [3] Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)
    Brandes, J.
    Kudrow, D.
    Klise, S.
    Krege, J. H.
    Case, M. G.
    Raskin, J.
    Khanna, R.
    Vasudeva, R.
    [J]. HEADACHE, 2019, 59 : 121 - 121
  • [4] Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
    Brandes, Jan Lewis
    Klise, Suzanne
    Krege, John H.
    Case, Michael
    Khanna, Rashna
    Vasudeva, Raghavendra
    Raskin, Joel
    Pearlman, Eric M.
    Kudrow, David
    [J]. CEPHALALGIA, 2019, 39 (11) : 1343 - 1357
  • [5] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION study
    Ashina, M.
    Roos, C.
    Ayer, D. W.
    Ruff, D.
    Krege, J. H.
    Li, L. Q.
    Komori, M.
    [J]. HEADACHE, 2022, 62 : 113 - 114
  • [6] Long-Term Treatment With Lasmiditan in Patients With Migraine: Results From the Open-Label Extension of the CENTURION Study
    Ashina, M.
    Roos, C.
    Ayer, D.
    Ruff, D.
    Krege, J.
    Li, L. Q.
    Komori, M.
    [J]. JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [7] A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine
    Croop, Robert
    Berman, Gary
    Kudrow, David
    Mullin, Kathleen
    Thiry, Alexandra
    Lovegren, Meghan
    L'Italien, Gilbert
    Lipton, Richard B.
    [J]. CEPHALALGIA, 2024, 44 (04)
  • [8] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Angelo Camporeale
    David Kudrow
    Ryan Sides
    Shufang Wang
    Annelies Van Dycke
    Katherine J. Selzler
    Virginia L. Stauffer
    [J]. BMC Neurology, 18
  • [9] A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine
    Camporeale, Angelo
    Kudrow, David
    Sides, Ryan
    Wang, Shufang
    Van Dycke, Annelies
    Selzler, Katherine J.
    Stauffer, Virginia L.
    [J]. BMC NEUROLOGY, 2018, 18
  • [10] Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial
    Ashina, Messoud
    Roos, Caroline
    Li, Lily Qian
    Komori, Mika
    Ayer, David
    Ruff, Dustin
    Krege, John Henry
    [J]. CEPHALALGIA, 2023, 43 (04)
12345